6855 Panoramica delle azioni Ascentage Pharma Group International, società di biotecnologie in fase clinica, sviluppa terapie per il cancro, il virus dell'epatite B cronica (HBV) e le malattie legate all'età nella Cina continentale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Ascentage Pharma Group International Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Ascentage Pharma Group International Prezzi storici delle azioni Prezzo attuale dell'azione HK$43.75 Massimo di 52 settimane HK$48.85 Minimo di 52 settimane HK$15.42 Beta 1.12 Variazione di 1 mese 8.02% Variazione a 3 mesi 3.67% Variazione di 1 anno 65.41% Variazione a 3 anni 72.24% Variazione a 5 anni n/a Variazione dall'IPO 19.21%
Notizie e aggiornamenti recenti
Ascentage Pharma Group International Announces Board and Committee Changes, Effective January 2, 2025 Jan 02 Ascentage Pharma Group International has filed a Follow-on Equity Offering in the amount of $100 million. Dec 28
Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax Dec 10
Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List Nov 28
Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors Nov 27
Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC Oct 08 Vedi altri aggiornamenti
Ascentage Pharma Group International Announces Board and Committee Changes, Effective January 2, 2025 Jan 02 Ascentage Pharma Group International has filed a Follow-on Equity Offering in the amount of $100 million. Dec 28
Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax Dec 10
Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List Nov 28
Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors Nov 27
Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC Oct 08
First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023) Oct 03
Forecast to breakeven in 2026 Aug 28
First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023) Aug 26
Ascentage Pharma Clears to Initiate A Registrational Phase III Study of Lisaftoclax, by the Center for Drug Evaluation of China National Medical Products Administration Aug 13
Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024 Aug 09
New minor risk - Shareholder dilution Jun 24
Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351) Jun 18
New minor risk - Share price stability Jun 17
Ascentage Pharma Group International Announces Board and Committee Changes Jun 13 Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%
Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting May 25
Ascentage Pharma Group International, Annual General Meeting, May 10, 2024 Mar 28
Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022) Mar 28
Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting Mar 06
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia Feb 14
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN) Jan 17
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib Dec 15
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR Dec 11
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication Nov 25
China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients Nov 18 Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports
Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc Oct 24
Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia Oct 18
Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE Oct 13
First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022) Aug 23
Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial Aug 22
Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023 Aug 10
Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax Aug 08
Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All) Jul 06
Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC Jun 06
Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST Jun 01
Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting May 29
Full year 2022 earnings released: CN¥3.35 loss per share (vs CN¥3.07 loss in FY 2021) Mar 23 Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million. Feb 02
Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List Jan 19
Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax Dec 14 Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib
Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License Nov 28
Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies Nov 10
Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B Nov 08
Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb Nov 07
Co-Founder recently bought HK$159k worth of stock Nov 06 Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting Nov 04
Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting Oct 20 Ascentage Pharma Announces Phase I/Ii Data of Olverembatinib (Hqp1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-In-Class Potential
First half 2022 earnings released: CN¥1.54 loss per share (vs CN¥1.53 loss in 1H 2021) Aug 29
Ascentage Pharma Group International to Report Q2, 2022 Results on Aug 26, 2022 Aug 17
High number of new directors Jul 31
Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada Jul 22
Ascentage Pharma Announces China National Medical Products Administration Accepts and Grants Priority Review Designation to Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML Jul 20 Ascentage Pharma Group International Announces Ind Clearance by the Us Fda for First-In-Human Study of Novel Eed Inhibitor Apg-5918
Ascentage Pharma Group International Releases Results from A Phase I Study of the Company's Novel Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R Nhl) at the 2022 European Hematology Association Hybrid Congress Jun 13
Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL Jun 09
Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC Jun 08 Ascentage Pharma Group International Releases the Updated Results from A Phase II Study of the Mdm2-P53 Inhibitor Alrizomadlin (APG-115) Plus Pembrolizumab in Adults and Children with Various Solid Tumors in A Poster Discussion Session At the ASCO Annual Meeting
Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development May 27
High number of new directors May 27
Ascentage Pharma Group to Present Latest Clinical Data of Bcl-2 Inhibitorlisaftoclax (Apg-2575) in Patients with Relapsed/Refractory Non-Hodgkinlymphomas At 2022 European Hematology Association Hybrid Congress May 24
Ascentage Pharma Group International Announces Management Changes, Effective May 20, 2022 May 20
Ascentage Pharma Group International Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in Embo Molecular Medicine May 19
Less than half of directors are independent Apr 27
Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 Apr 14
Ascentage Pharma Group International, Annual General Meeting, May 19, 2022 Mar 23
Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including A China Study Demonstrating Complete Responses Dec 15
Ascentage Pharma Announces CDE's Approval for the Phase II Pivotal Study in China of the Bcl-2 Inhibitor Lisaftoclax (APG-2575) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Dec 13
Clover Biopharmaceuticals, Ltd. and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human Trail-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis Dec 10
Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib Dec 01
Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Grants Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma Sep 24
Ascentage Pharma Reports the Phase Ib Results of the Dual Bcl-2/Bcl-Xl Inhibitor, Apg-1252 Sep 10
First half 2021 earnings released: CN¥1.53 loss per share (vs CN¥1.53 loss in 1H 2020) Aug 29
Ascentage Pharma Group International Receives Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma Jul 23
Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors Jun 15 Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs
Non-Executive Director recently sold HK$19m worth of stock Jun 01
Forecast to breakeven in 2023 May 26
Ascentage Pharma to Announce Updated Results Demonstrating Clinical Potential of Alrizomadlin (APG-115) Plus Pembrolizumab in Patients with Advanced Solid Tumors that Had Failed Immunotherapies in Oral Presentation May 21
Non-Executive Director has left the company Apr 07
Full year 2020 earnings released: CN¥3.14 loss per share (vs CN¥12.69 loss in FY 2019) Apr 02
Ascentage Pharma Group International to Report Fiscal Year 2020 Results on Mar 31, 2021 Mar 20
Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020, Demonstrating Therapeutic Potential in STK11-Mutant Non-Small Cell Lung Cancer Feb 03 Rendimenti per gli azionisti 6855 HK Biotechs HK Mercato 7D -1.8% -3.2% -2.1% 1Y 65.4% -7.7% 16.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 6855 ha superato il Hong Kong Biotechs che ha restituito -7.7 % nell'ultimo anno.
Rendimento vs Mercato: 6855 ha superato il mercato Hong Kong che ha restituito 16.9 % nell'ultimo anno.
Volatilità dei prezzi Is 6855's price volatile compared to industry and market? 6855 volatility 6855 Average Weekly Movement 6.4% Biotechs Industry Average Movement 9.4% Market Average Movement 7.9% 10% most volatile stocks in HK Market 15.8% 10% least volatile stocks in HK Market 3.6%
Prezzo delle azioni stabile: 6855 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di 6855 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 2009 574 Dajun Yang www.ascentage.cn
Ascentage Pharma Group International, società di biotecnologie in fase clinica, sviluppa terapie per il cancro, il virus dell'epatite B cronica (HBV) e le malattie legate all'età nella Cina continentale. Il principale prodotto candidato dell'azienda è HQP1351, un inibitore di BCR-ABL che ha come bersaglio i mutanti di BCR-ABL1, compresi quelli con la mutazione T315I. Sviluppa inoltre APG-2575, un inibitore selettivo di Bcl-2 somministrato per via orale per tumori ematologici e solidi; APG-115, un inibitore orale di piccole molecole delle interazioni proteina-proteina MDM2-p53 per il trattamento di tumori solidi e tumori ematologici; e APG-1252, un farmaco a piccola molecola che ripristina l'apoptosi attraverso la doppia inibizione delle proteine Bcl-2 e Bcl-xL per il trattamento del carcinoma polmonare a piccole cellule, del carcinoma polmonare non a piccole cellule, del tumore neuroendocrino e del linfoma non Hodgkin.
Mostra di più Ascentage Pharma Group International Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Ascentage Pharma Group International con la sua capitalizzazione di mercato? 6855 statistiche fondamentali Capitalizzazione di mercato HK$13.56b Guadagni(TTM ) -HK$382.85m Ricavi(TTM ) HK$959.60m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 6855 Conto economico (TTM ) Ricavi CN¥903.03m Costo del fatturato CN¥27.45m Profitto lordo CN¥875.58m Altre spese CN¥1.24b Guadagni -CN¥360.28m
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -1.16 Margine lordo 96.96% Margine di profitto netto -39.90% Rapporto debito/patrimonio netto 216.3%
Come si è comportato 6855 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/04 08:41 Prezzo dell'azione a fine giornata 2025/01/03 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Ascentage Pharma Group International è coperta da 13 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Yang Huang BofA Global Research Jin Zhang China International Capital Corporation Limited Wangbin Zhou China International Capital Corporation Limited
Mostra 10 altri analisti 